U.S. FDA Strikes Again, Now Bans Ranbaxy’s Toansa API Facility; Company Apologizes To Stakeholders
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has issued a ban on products from Ranbaxy’s Toansa plant following observations of GMP violations as part of its inspections earlier this month. The latest regulatory action jeopardizes Ranbaxy’s U.S. operations.